How many institutional investors hold AVTX?

2 tracked institutional investors disclosed a position in AVTX (AVALO THERAPEUTICS INC) in their most recent 13F filing.

Who is the largest institutional holder of AVTX?

Steve Cohen, Point72 Asset Management, holds the largest disclosed position in AVTX, valued at $44M.

Where does this AVTX ownership data come from?

SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.

AVTX — AVALO THERAPEUTICS INC

Name: AVALO THERAPEUTICS INC (AVTX) — Institutional Ownership
Creator: InvestorLens
License: https://www.sec.gov/about/website-policies

Public company

For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

Why are billionaires buying AVTX?

Built from public SEC filings and public economic data. Not a recommendation.

Confidence

Institutional Conviction

Net distribution · 2 buying vs 1 selling last quarter

Macro Tailwind

Macro conditions are mixed for this sector

Why? — Evidence & Confidence ▾

Of 3 tracked investors who changed their AVTX position last quarter, 2 bought and 1 sold (67% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 55/100 in a Squeeze regime).

Supporting evidence

+2 tracked investors added or increased positions last quarter (Ken Griffin, Steve Cohen)
+2 tracked investors reported holding AVTX at their latest filing
+Macro Health is 55/100 in a Squeeze regime — historically acceptable for this sectorsource

Contradicting evidence — always shown

−1 tracked investor reduced or exited last quarter (0 reduced, 1 sold out)
−13F data is disclosed up to 45 days after quarter end — positions may have changed since

Know the limits

· 13F disclosure lag (up to 45 days)
· Tracked investors are a sample, not the whole market
· Sector regime fit is a historical average, not a guarantee

Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 8/20/2026.

About AVALO THERAPEUTICS INC (AVTX)

AVALO THERAPEUTICS INC (AVTX) appears in the most recent 13F filings of 2 tracked institutional investors. The largest disclosed position is held by Steve Cohen (Point72 Asset Management), valued at $44M. Across recent filings, tracked investors recorded 1 new positions, 5 increased, 1 reduced, and 1 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in AVTX

/100

Institutional Accumulation

Added / Increased6

Reduced1

Exited1

BearishBullish

Crowded Trade Score™

How many top investors track AVTX

/100

Undiscovered

2investors

Only 2 tracked investors report this position.

UndiscoveredCrowded

151015+

AVTX Ownership Composition

How AVALO THERAPEUTICS INC is held across tracked investor types, based on reported 13F positions.

Dominant Type

Multi-Strategy / Quant

100% of tracked value

Institutions

tracked investors

Total Reported

$52.4M

combined 13F value

Multi-Strategy / Quant100.0%

Multi-Strategy / Quant(2)

100.0%

Tracked investors currently reporting AVTX

1 tracked investor has since exited this position — listed separately below.

Investor	Firm	Shares	Market value	% of portfolio	As of
Steve Cohen	Point72 Asset Management	2.4M	$44.1M	0.05%	Jun 30, 2026
Ken Griffin	Citadel Advisors	450.2K	$8.3M	0.00%	Jun 30, 2026

Steve CohenJun 30, 2026
Point72 Asset Management
Shares
2.4M
Value
$44.1M
% Portfolio
0.05%
Ken GriffinJun 30, 2026
Citadel Advisors
Shares
450.2K
Value
$8.3M
% Portfolio
0.00%

Previously held AVTX

These investors reported AVTX in an earlier quarter but not in their most recent 13F. Figures below are their last reported position, not a current holding.

Investor	Firm	Last reported shares	Value then	Last held
Izzy Englander	Millennium Management	835.5K	$12.5M	Mar 31, 2026

Recent activity

Investor	Action	Δ %	Current value	Filing date
Izzy Englander	Increased	380.23%	$12M	Feb 17, 2026
Izzy Englander	Increased	26.59%	$12.5M	May 15, 2026
Izzy Englander	Sold	-100.00%	$0	Aug 14, 2026
Ken Griffin	Increased	72.81%	$8.3M	Aug 14, 2026
Steve Cohen	New	—	$13.4M	Nov 14, 2025
Steve Cohen	Reduced	-40.46%	$11.4M	Feb 17, 2026
Steve Cohen	Increased	46.00%	$13.7M	May 15, 2026
Steve Cohen	Increased	160.55%	$44.1M	Aug 14, 2026

Izzy Englander
Increased
$12M(380.23%)Feb 17, 2026
Izzy Englander
Increased
$12.5M(26.59%)May 15, 2026
Izzy Englander
Sold
$0(-100.00%)Aug 14, 2026
Ken Griffin
Increased
$8.3M(72.81%)Aug 14, 2026
Steve Cohen
New
$13.4MNov 14, 2025
Steve Cohen
Reduced
$11.4M(-40.46%)Feb 17, 2026
Steve Cohen
Increased
$13.7M(46.00%)May 15, 2026
Steve Cohen
Increased
$44.1M(160.55%)Aug 14, 2026

Frequently asked questions

How many institutional investors hold AVTX?: 2 tracked institutional investors disclosed a position in AVTX (AVALO THERAPEUTICS INC) in their most recent 13F filing.
Who is the largest institutional holder of AVTX?: Steve Cohen, Point72 Asset Management, holds the largest disclosed position in AVTX, valued at $44M.
Did institutional ownership of AVTX increase or decrease?: Across recent 13F filings, tracked investors recorded 1 new positions, 5 increased, 1 reduced, and 1 fully exited AVTX.
Where does this AVTX ownership data come from?: SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.